Close Menu

NEW YORK (360Dx) – Indivumed and Flagship Biosciences today announced a partnership to expand their tissue-based biomarker development capabilities and clinical services to support advanced oncology diagnostics.

Under the terms of the agreement, the companies will offer services that combine Flagship’s experience in biomarker development and Indivumed’s multiplex immunohistochemistry assay development capabilities.

Financial and other terms of the agreement were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.